⌕
Alto Neuroscience · ANRO · NYSE
Tenet 52 · Mixed
Compare
$27.12−8.19%At closeTenet 52 · Mixed
$27.12−2.42 (−8.19%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD

Alto Neuroscience (ANRO) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Zacks Investment ResearchNov 16, 2026 · 13:01 ET
Alto Neuroscience, Inc. (ANRO) Upgraded to Buy: Here's What You Should Know

Alto Neuroscience, Inc. (ANRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).…

● Zacks Investment ResearchNov 16, 2026 · 10:55 ET
Wall Street Analysts Predict a 29.38% Upside in Alto Neuroscience, Inc. (ANRO): Here's What You Should Know

The mean of analysts' price targets for Alto Neuroscience, Inc. (ANRO) points to a 29.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in …

● Business WireNov 10, 2026 · 16:05 ET
Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatri…

● Defense WorldNov 7, 2026 · 05:15 ET
Alto Neuroscience (NYSE:ANRO) Stock Price Crosses Above 200-Day Moving Average – Here’s What Happened

Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $24.32 and traded as high a…

● Business WireNov 4, 2026 · 06:57 ET
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatri…

● Zacks Investment ResearchOct 14, 2026 · 11:01 ET
Here's Why You Should Add ANRO Stock to Your Portfolio Now

Alto advances its depression drug pipeline, with key 2027 study results ahead for ALTO-207, ALTO-300 and ALTO-100.…

● Business WireSep 9, 2026 · 08:03 ET
Alto Neuroscience Announces Participation in Upcoming Investor Conferences

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatri…

● Defense WorldAug 31, 2026 · 02:16 ET
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $37.25 Average PT from Analysts

Shares of Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven analysts that are presently covering the stock, Marketbeat.com reports. One research ana…

● Business WireAug 27, 2026 · 16:05 ET
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced…

● Defense WorldAug 26, 2026 · 03:54 ET
AWM Investment Company Inc. Purchases New Holdings in Alto Neuroscience, Inc. $ANRO

AWM Investment Company Inc. bought a new position in shares of Alto Neuroscience, Inc. (NYSE: ANRO) during a recent quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 80…

● Defense WorldAug 25, 2026 · 03:47 ET
Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High – Still a Buy?

Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $36.99 and last traded at $36.4220, with a volume of 867909 sha…

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just ANRO · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.